Quantitative Integrative Survival Prediction in Multiple Myeloma Patients Treated With Bortezomib-Based Induction, High-Dose Therapy and Autologous Stem Cell Transplantation.
Manuela HummelThomas HielscherMartina Emde-RajaratnamHans J SalwenderSusanne BeckChristof ScheidUta BertschHartmut GoldschmidtAnna JauchJérôme MoreauxAnja SeckingerDirk HosePublished in: JCO precision oncology (2024)
In summary, we developed and validated individual quantitative nomogram-based OS prediction. Continuous risk assessment integrating molecular prognostic factors is superior to R-ISS, R2-ISS, or Mayo-2022-score alone.